Q3 2024 Earnings Forecast for ANI Pharmaceuticals, Inc. Issued By HC Wainwright (NASDAQ:ANIP)

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) - Research analysts at HC Wainwright cut their Q3 2024 earnings per share estimates for ANI Pharmaceuticals in a research report issued to clients and investors on Tuesday, September 17th. HC Wainwright analyst O. Livnat now expects that the specialty pharmaceutical company will earn $0.75 per share for the quarter, down from their prior forecast of $0.82. HC Wainwright currently has a "Buy" rating and a $94.00 target price on the stock. The consensus estimate for ANI Pharmaceuticals' current full-year earnings is $3.50 per share.

Other research analysts have also recently issued research reports about the company. Truist Financial reaffirmed a "hold" rating and set a $60.00 target price (down previously from $80.00) on shares of ANI Pharmaceuticals in a research report on Wednesday, September 11th. StockNews.com lowered shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, September 7th. Finally, Raymond James raised their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research report on Wednesday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, ANI Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $78.80.

ANI Pharmaceuticals Stock Down 1.1 %

ANIP traded down $0.67 during midday trading on Thursday, reaching $60.38. 224,984 shares of the company were exchanged, compared to its average volume of 207,445. The company has a market cap of $1.27 billion, a price-to-earnings ratio of 38.16 and a beta of 0.71. ANI Pharmaceuticals has a one year low of $48.20 and a one year high of $70.81. The company's fifty day moving average price is $61.22 and its 200 day moving average price is $63.78. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.07. The firm had revenue of $138.00 million for the quarter, compared to the consensus estimate of $129.09 million. ANI Pharmaceuticals had a net margin of 5.01% and a return on equity of 15.64%. The business's revenue was up 18.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.06 earnings per share.

Insider Buying and Selling

In other news, COO Muthusamy Shanmugam sold 20,000 shares of the firm's stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $58.90, for a total transaction of $1,178,000.00. Following the completion of the sale, the chief operating officer now owns 682,620 shares in the company, valued at approximately $40,206,318. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 66,007 shares of company stock valued at $4,089,790. 12.70% of the stock is owned by insiders.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANIP. Innealta Capital LLC purchased a new stake in ANI Pharmaceuticals during the 2nd quarter worth about $65,000. Ridgewood Investments LLC purchased a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $85,000. SG Americas Securities LLC bought a new position in shares of ANI Pharmaceuticals in the first quarter valued at approximately $106,000. ADAR1 Capital Management LLC purchased a new position in ANI Pharmaceuticals during the fourth quarter valued at approximately $132,000. Finally, Clear Street Markets LLC bought a new stake in ANI Pharmaceuticals during the 4th quarter worth approximately $140,000. 76.05% of the stock is currently owned by institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.